CD247, a novel T cell-derived diagnostic and prognostic biomarker for detecting disease progression and severity in patients with type 2 diabetes

Diabetes Care

Volumn 38, Issue 1, 2015, Pages 113-118

  Eldor, Roy ^a   Klieger, Yair ^b,c   Sade Feldman, Moshe ^b   Vaknin, Ilan ^b   Varfolomeev, Inna ^b   Fuchs, Camil ^d   Baniyash, Michal ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c ImProDia Ltd   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; CD247 ANTIGEN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; SULFONYLUREA; UNCLASSIFIED DRUG; CD3 ANTIGEN; CD3 ANTIGEN, ZETA CHAIN;

ADULT; ANAMNESIS; ANTIGEN EXPRESSION; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC FOOT; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DOWN REGULATION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PHYSICAL EXAMINATION; PROGNOSIS; T LYMPHOCYTE; AGED; CASE CONTROL STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; GENETICS; INFLAMMATION; METABOLISM; MIDDLE AGED; NORMAL HUMAN;

ADULT; AGED; ANTIGENS, CD3; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; T-LYMPHOCYTES;

EID: 84920062133     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-1544     Document Type: Article

References (19)

1. Garcia C, Feve B, Ferré P, et al. Diabetes and inflammation: Fundamental aspects and clinical implications. Diabetes Metab 2010;36:327-338
2. Jin C, Lu L, Zhang RY, et al. Association of serum glycated albumin, C-reactive protein and ICAM-1 levels with diffuse coronary artery disease in patients with type 2 diabetes mellitus. Clin Chim Acta 2009;408:45-49
3. Kornum JB, Thomsen RW, Riis A, Lervang HH, Schønheyder HC, Sørensen HT. Type 2 diabetes and pneumonia outcomes: A population-based cohort study. Diabetes Care 2007;30:2251-2257
4. Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006;24:33-50
5. Abrahamian H, Endler G, Exner M, et al. Association of low-grade inflammation with nephropathy in type 2 diabetic patients: Role of elevated CRP-levels and 2 different genepolymorphisms of proinflammatory cytokines. Exp Clin Endocrinol Diabetes 2007; 115:38-41
6. Del Cañizo Gómez FJ, Fernández Pérez C, Moreno Ruiz I, et al. Microvascular complications and risk factors in patients with type 2 diabetes. Endocrinol Nutr 2011;58:163-168
7. Navarro JF, Mora C, Maca M, Garca J. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis 2003;42:53-61
8. Fronczyk A, Moleda P, Safranow K, Piechota W, Majkowska L. Increased concentration of Creactive protein in obese patients with type 2 diabetes is associated with obesity and presence of diabetes but not with macrovascular and microvascular complications or glycemic control. Inflammation 2014;37:349-357
9. Baniyash M. TCR zeta-chain downregulation: Curtailing an excessive inflammatory immune response. Nat Rev Immunol 2004;4:675-687
10. Irving BA, Weiss A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 1991;64:891-901
11. Weiss A, Irving BA, Tan LK, Koretzky GA. Signal transduction by the T cell antigen receptor. Semin Immunol 1991;3:313-324
12. Bronstein-Sitton N, Cohen-Daniel L, Vaknin I, et al. Sustained exposure to bacterial antigen induces interferon-gamma-dependent T cell receptor zeta down-regulation and impaired T cell function. Nat Immunol 2003;4:957-964
13. Lahdenperä AI, Fälth-Magnusson K, Högberg L, Ludvigsson J, Vaarala O. Expression pattern of T-helper 17 cell signaling pathway and mucosal inflammation in celiac disease. Scand J Gastroenterol 2014;49:145-156
14. Grundy S, Plumb J, Lea S, Kaur M, Ray D, Singh D. Down regulation of T cell receptor expression in COPD pulmonary CD8 cells. PLoS ONE 2013;8:e71629
15. Gorman CL, Russell AI, Zhang Z, Cunninghame Graham D, Cope AP, Vyse TJ. Polymorphisms in the CD3Z gene influence TCRzeta expression in systemic lupus erythematosus patients and healthy controls. J Immunol 2008;180:1060-1070
16. Di Angelantonio E, Gao P, Khan H, et al.; Emerging Risk Factors Collaboration. Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA 2014;311:1225-1233
17. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
18. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
19. Bogaty P, Brophy JM, Boyer L, et al. Fluctuating inflammatory markers in patients with stable ischemic heart disease. Arch Intern Med 2005;165:221-226